Simone Seechi, R&D Process Chemist at Olon and Matthieu Culié, Head of Development & GMP Manufacturing at GTP Bioways were...
Interview – Challenges in the Development & Manufacturing of ADCs
read more
Choosing a Biologics CDMO: Your Blueprint for Success
In the dynamic and high-stakes world of biologics, selecting the right Contract Development and Manufacturing Organisation (CDMO) can make...
Mastering Complex Protein Purification: A Case Study on Achieving Optimal Downstream Processing
Case study: Effective removal of host cell proteins in high pI recombinant protein production The production of complex recombinant...
Overcoming Challenges in ADC Purification: A Case Study
Case study: Purification of an ADC to remove the residual free drug Among bioconjugates, antibody-drug conjugates (ADCs) represent a...
Why Choosing a Client-Centric CDMO for the Manufacturing of Your Biologics is Critical to the Success of Your Project?
In the rapidly evolving landscape of biopharmaceutical development, finding the right Contract Development and Manufacturing Organization...
Use of an innovative viral inactivation method for a complex recombinant protein to be used as vaccine for COVID-19
Case study: Use of an innovative viral inactivation method for a complex recombinant protein to be used as vaccine for COVID-19 When...
Antibody-Drug Conjugates (ADC) and their potential therapeutic applications
In the dynamic landscape of therapeutic development, antibody-drug conjugates (ADCs) have emerged as a ground-breaking class of...
A review of the therapeutic use of monoclonal antibodies
Therapeutic monoclonal antibodies (mAbs) have become a dominant product class within the biopharmaceutical market. To date, therapeutic...
